89bio Inc (NAS:ETNB)

$ 9.23 -0.06 (-0.65%) Market Cap: 977.55 Mil Enterprise Value: 479.87 Mil PE Ratio: 0 PB Ratio: 1.88 GF Score: 38/100

89Bio Inc at H.C. Wainwright & Co LLC 7th Annual NASH Investor Conference (Virtual) Transcript
Oct 24, 2023
89Bio Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
Sep 26, 2023
89Bio Inc at RBC Capital Markets Global Healthcare Conference Transcript
May 17, 2023
89Bio Inc at Bank of America Global Healthcare Conference Transcript
May 09, 2023
89Bio Inc Topline Results from Phase 2b ENLIVEN Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis - Corporate Call Transcript
Mar 22, 2023
89Bio Inc at SVB Securities Global Biopharma Conference (Virtual) Transcript
Feb 15, 2023
89Bio Inc at H C Wainwright NASH Investor Conference (Virtual) Transcript
Oct 17, 2022
89Bio Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Sep 12, 2022
89Bio Inc at Bank of America Healthcare Conference Transcript
May 10, 2022

89Bio Inc Topline Results from Phase 2b ENLIVEN Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis - Corporate Call Transcript

Mar 22, 2023 / 12:00PM GMT

Release Date Price: $13.68 (+25.16%)

Transcript

Operator

Greetings. Welcome to 89bio reports topline results from Phase 2b ENLIVEN trial of pegozafermin in patients with non-alcoholic steatohepatitis. (Operator Instructions) Please note, this conference is being recorded.

At this time, I will now turn the conference over to Ryan Martins, Chief Financial Officer of 89bio. Ryan, you may now begin.

Ryan Martins

89bio, Inc. - CFO

Thank you, operator. Good morning, and welcome to today's call.

The press release reporting the topline results from ENLIVEN is available in the Investors section of our website, 89 bio.com, under Press Releases. And today's presentation will be posted under Events and Presentations after our call concludes. Today, I'm joined by Rohan Palekar, our Chief Executive Officer; Dr. Hank Mansbach, our Chief Medical Officer.

Before we begin, I'd like to remind you that statements made during this conference call that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.